Disclosed is the use of a multivalent meningococcal vaccine comprised of immunologically effective amounts of four distinct protein-polysaccharide conjugates for the manufacture of a medicament for protecting a human against infection by N. meningitidis, wherein each of the conjugates contains a different capsular polysaccharide conjugated to a carrier protein, and wherein the capsular polysaccharides are prepared from serogroups A, C, W-135 and Y of N. meningitidis, further wherein the carrier protein is either diphtheria toxoid or CRM197.
